WOCKPHARMA

Wockhardt share price & financials

Price
₹2,011.1
Market cap
₹35.4k Cr
Sector
Healthcare
Calls analysed
3
Latest concall · Q4 FY26 · call held 04 Jun 2026

Wockhardt Q4 FY26

Revenue ₹3,373 cr EBITDA ₹630 cr +51%EBITDA Margin 18.6%

What went well

  • Top line revenue for FY26 stood at INR 3,373 crores.
  • EBITDA for FY26 was INR 630 crores, representing a 51% growth.
  • Profitability before tax for FY26 reached INR 238 crores.

What to watch

  • The new business model for Zaynich launch is expected to have a 'slight negative impact on profitability' in the initial 12-18 months due to upfront costs.
  • FDA approval timelines for new products like Foviscu are 'not predictable nowadays'.
Read the full call →

What Wockhardt does

Wockhardt is a global research-led healthcare company operating across three lines: novel antibiotic discovery targeting antimicrobial resistance, an integrated diabetes-biosimilars franchise spanning human insulin and insulin analogues, and branded/specialty pharmaceuticals sold in India and international markets including the UK, Ireland and emerging markets. It earns by manufacturing and selling branded generic drugs and specialty injectables through its own facilities and country subsidiaries (including UK-based Pinewood), and by licensing/commercializing its novel antibiotic pipeline, most notably Zaynich, which became the first Indian-discovered drug to receive US FDA approval.

Segments

  • Novel Antibiotics
  • Biotechnology
  • Pharmaceuticals
Manufacturing facilities
11, across the globe
R&D centers
2 (India and UK)
Biosimilar products commercialized
2 (Recombinant Human Insulin, Glargine)
Biosimilar pipeline assets (R&D through Phase III)
5 (Aspart R, Aspart 30/70, Degludec, Degludec+Aspart, Semaglutide)
Emerging markets with biosimilars registered & actively supplied
30+ markets
UK subsidiary market position
Pinewood holds market leadership in Methadone, Pinamox, Codeine, Flucillin and Cortopin
Headquarters Wockhardt Towers, Bandra-Kurla Complex, Bandra (East), Mumbai 400051 Company website

Guidance record · Q4 FY26

what the last two calls moved 15 tracked 1 delivered 4 missed 10 open
  • PBT Positive Status missed said Q3 FY23 Promised: turn completely PBT positive in 2 years from now Q4 FY26: Company reported PBT of INR 238 crores for FY26. This confirms the target for FY25 was not met.
  • Biosimilar Capacity revised up said Q4 FY25 Promised: double our capacities over the next 24 months and put up new facility Q4 FY26: Timeline accelerated: 'we will double our capacity in the next 12 to 15 months.'
  • Biosimilar Business Size on track said Q4 FY25 Promised: expect to double the business in the next 3 years Q4 FY26: Management reiterated the goal to double the business in the next 24-36 months. The business grew 27% in FY26, showing strong progress.

All 15 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 35.8%, net profit up 55.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue370 325 355 413 380 +3%430 +32%516 +45%561 +36%
EBITDA49 62 106 131 113 +131%113 +82%161 +52%158 +21%
Net profit-36 -22 40 69 54 +250%28 +227%167 +318%107 +55%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +39.7% 1Y

₹1.5k₹2.0kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q4 FY26 — 4 Jun 2026

1Y: ₹1,559.9 on 10 Sept 2025 → ₹2,179.4. High ₹2,248.8 (9 Sept 2026), low ₹1,100.3 (23 Mar 2026).

How the price took the results

close before → close after

Q4 FY26
−0.0%
4 Jun

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue fell 13.1% a year over 3 years, FY23 to FY26. Operating margin widened to 29.8%.

Year endingFY23FY24FY25FY26
Revenue₹2.7k Cr₹1.2k Cr₹1.4k Cr₹1.7k Cr
Operating profit₹75 Cr₹-36 Cr₹297 Cr₹518 Cr
Operating margin2.8%-3.1%21.2%29.8%
Interest₹302 Cr₹237 Cr₹199 Cr₹176 Cr
Depreciation₹251 Cr₹176 Cr₹168 Cr₹186 Cr
Net profit₹-621 Cr₹-422 Cr₹-12 Cr₹318 Cr
Net margin-23.4%-36.6%-0.9%18.3%
Cash from operations₹71 Cr₹188 Cr₹-14 Cr₹241 Cr
Free cash flow₹63 Cr₹100 Cr₹-508 Cr₹-26 Cr
ROCE-1.0%-4.0%4.0%10.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹55 Cr₹72 Cr₹72 Cr₹77 Cr₹81 Cr₹81 Cr
Reserves₹1.6k Cr₹2.1k Cr₹1.7k Cr₹1.7k Cr₹4.5k Cr₹3.0k Cr
Borrowings₹2.1k Cr₹2.0k Cr₹2.0k Cr₹2.1k Cr₹2.5k Cr₹2.0k Cr
Other liabilities₹1.2k Cr₹1.6k Cr₹966 Cr₹936 Cr₹1.5k Cr₹887 Cr
Total liabilities₹4.9k Cr₹5.8k Cr₹4.7k Cr₹4.9k Cr₹8.5k Cr₹5.9k Cr
Fixed assets₹1.7k Cr₹1.8k Cr₹1.6k Cr₹1.4k Cr₹4.4k Cr₹1.4k Cr
Capital work in progress₹716 Cr₹825 Cr₹823 Cr₹833 Cr₹583 Cr₹1.4k Cr
Investments₹297 Cr₹297 Cr₹297 Cr₹297 Cr₹696 Cr₹709 Cr
Other assets₹2.2k Cr₹2.8k Cr₹2.0k Cr₹2.3k Cr₹2.9k Cr₹2.5k Cr
Total assets₹4.9k Cr₹5.8k Cr₹4.7k Cr₹4.9k Cr₹8.5k Cr₹5.9k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public added +1.84 pp while DIIs trimmed −1.76 pp. The shareholder count grew 13% to 1,66,518.

Promoters
49.1%
FIIs
7.2%
DIIs
9.2%
Government
0.0%
Public
34.4%

Since Jun 2025

  • Public +1.84 pp
  • DIIs −1.76 pp
  • FIIs −0.06 pp

How it drifted, 12 quarters

Over this window DIIs went from 0.2% to 9.2% — +9.0 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 55.1%, FIIs 3.0%, DIIs 0.2%, Public 41.6%.Dec '23: Promoters 54.9%, FIIs 4.2%, DIIs 0.3%, Public 40.6%.Mar '24: Promoters 51.6%, FIIs 5.5%, DIIs 4.8%, Government 0.0%, Public 38.1%.Jun '24: Promoters 52.0%, FIIs 5.9%, DIIs 4.5%, Government 0.0%, Public 37.6%.Sep '24: Promoters 52.0%, FIIs 6.7%, DIIs 5.1%, Government 0.0%, Public 36.2%.Dec '24: Promoters 49.1%, FIIs 6.5%, DIIs 9.8%, Government 0.0%, Public 34.5%.Mar '25: Promoters 49.1%, FIIs 6.8%, DIIs 10.6%, Government 0.0%, Public 33.5%.Jun '25: Promoters 49.1%, FIIs 7.3%, DIIs 11.0%, Government 0.0%, Public 32.6%.Sep '25: Promoters 49.1%, FIIs 7.1%, DIIs 11.0%, Government 0.0%, Public 32.8%.Dec '25: Promoters 49.1%, FIIs 7.0%, DIIs 10.6%, Government 0.0%, Public 33.4%.Mar '26: Promoters 49.1%, FIIs 7.1%, DIIs 11.0%, Government 0.0%, Public 32.8%.Jun '26: Promoters 49.1%, FIIs 7.2%, DIIs 9.2%, Government 0.0%, Public 34.4%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Wockhardt above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Themisto Trustee Company Private Limited 40.15%unchanged
Pasithee Trustee Company Private Limited 2.72%unchanged
Ananke Trustee Company Private Limited 2.35%unchanged
Tata Mutual Fund - Tata Small Cap Fund Mutual fund2.03%−0.07 pp
Callirhoe Trustee Company Private Limited 1.92%unchanged
Rekha Jhunjhunwala 1.75%unchanged
HSBC Mutual Fund - HSBC Small Cap Fund Mutual fund1.30%−0.08 pp
3P India Equity Fund 1 AIF1.15%−0.50 pp
Habil F Khorakiwala 0.37%unchanged
Murtaza Habil Khorakiwala 0.18%unchanged
Huzaifa Habil Khorakiwala 0.17%unchanged
Palanpur Holdings and Investments Private Limited 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in WOCKPHARMA

Filings to Aug 2026

0 new, 6 added, 1 trimmed, 0 sold out — net +0.08 L shares (+0.6%).

Held by funds
₹251 Cr
10 schemes
Biggest holder
HDFC Large and Mid Cap Fund
₹64 Cr · 0.2% of that fund
SchemeHoldingLast month
HDFC Large and Mid Cap Fund HDFC Mutual Fund₹64 Crheld
HDFC Manufacturing Fund HDFC Mutual Fund₹59 Crheld
HDFC Pharma and Healthcare Fund HDFC Mutual Fund₹56 Crheld
Nippon India Nifty Pharma ETF Nippon India Mutual Fund₹27 Cr+0.02 L
Nippon India Nifty Smallcap 250 Index Fund Nippon India Mutual Fund₹25 Cr+0.02 L
SBI Nifty Smallcap 250 Index Fund SBI Mutual Fund₹13 Cr+0.01 L
HDFC MNC Fund HDFC Mutual Fund₹6 Cr+0.03 L
Nippon India Nifty 500 Equal Weight Index Fund Nippon India Mutual Fund₹1 Cr+0.00 L

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Aug 2026

6 added, 1 trimmed — net +7,802 shares (+0.6%)

Funds are sitting on
+52%
vs est. average cost
Held by funds
₹251 Cr
10 schemes · ≈ 0.73% of the company
Biggest holder
HDFC Large and Mid Cap Fund
₹64 Cr · 0.2% of that fund
Longest holder
HDFC Pharma and Healthcare Fund
2y 5m · since Mar '24

Shares held by these funds +3931%

Dec '22 12.89 L shares Jul '26

All earnings calls (3)

Read the Q4 FY26 call →

Learn to analyse Wockhardt

Guides on how to read this kind of business and the numbers that matter.